ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved..
Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target specificity with consequent increase in side-effects and off-target toxicities resulting in dose reduction and drug discontinuation are some of the major issues with MKIs. To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA). The results of these trials showed marked and durable antitumour activity and manageable toxicity profiles in patients with RET-altered tumours. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of RET gene alterations, their potential applications and strategies for the implementation of a rational approach for the detection of RET fusion genes and mutations in human malignancies. We present here recommendations for the routine clinical detection of targetable RET rearrangements and mutations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 32(2021), 3 vom: 14. März, Seite 337-350 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belli, C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2020.11.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320184986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320184986 | ||
| 003 | DE-627 | ||
| 005 | 20231225173036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2020.11.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320184986 | ||
| 035 | |a (NLM)33455880 | ||
| 035 | |a (PII)S0923-7534(20)43197-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belli, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target specificity with consequent increase in side-effects and off-target toxicities resulting in dose reduction and drug discontinuation are some of the major issues with MKIs. To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA). The results of these trials showed marked and durable antitumour activity and manageable toxicity profiles in patients with RET-altered tumours. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of RET gene alterations, their potential applications and strategies for the implementation of a rational approach for the detection of RET fusion genes and mutations in human malignancies. We present here recommendations for the routine clinical detection of targetable RET rearrangements and mutations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a RET | |
| 650 | 4 | |a fluorescence in situ hybridization | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 7 | |a pralsetinib |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a RET protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a selpercatinib |2 NLM | |
| 650 | 7 | |a CEGM9YBNGD |2 NLM | |
| 700 | 1 | |a Penault-Llorca, F |e verfasserin |4 aut | |
| 700 | 1 | |a Ladanyi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Normanno, N |e verfasserin |4 aut | |
| 700 | 1 | |a Scoazec, J-Y |e verfasserin |4 aut | |
| 700 | 1 | |a Lacroix, L |e verfasserin |4 aut | |
| 700 | 1 | |a Reis-Filho, J S |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, V |e verfasserin |4 aut | |
| 700 | 1 | |a Gainor, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Endris, V |e verfasserin |4 aut | |
| 700 | 1 | |a Repetto, M |e verfasserin |4 aut | |
| 700 | 1 | |a Drilon, A |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, A |e verfasserin |4 aut | |
| 700 | 1 | |a André, F |e verfasserin |4 aut | |
| 700 | 1 | |a Douillard, J-Y |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 32(2021), 3 vom: 14. März, Seite 337-350 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:3 |g day:14 |g month:03 |g pages:337-350 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2020.11.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 3 |b 14 |c 03 |h 337-350 | ||